Population Effectiveness of Dolutegravir Implementation in Uganda: A Prospective Observational Cohort Study (DISCO), 48-Week Results

Simple item page
dc.contributor.authorSuzanne, M. McCluskey
dc.contributor.authorMuyindike, Winnie R.
dc.contributor.authorNanfuka, Victoria
dc.contributor.authorOmoding, Daniel
dc.contributor.authorNimusiima, Komukama
dc.contributor.authorBarigye, Ian T.
dc.contributor.authorKansiime, Lydia
dc.contributor.authorTumusiime, Justus
dc.contributor.authorTaing, N. Aung
dc.contributor.authorAshley, Stuckwisch
dc.contributor.authorBethany, Hedt-Gauthier
dc.contributor.authorVincent, C. Marconi
dc.contributor.authorMahomed-Yunus, S. Moosa
dc.contributor.authorDeenan, Pillay
dc.contributor.authorJennifer, Giandhari
dc.contributor.authorRichard, Lessells
dc.contributor.authorRavindra, K. Gupta
dc.contributor.authorMark, J. Siedner
dc.date.accessioned2025-04-02T20:12:07Z
dc.date.available2025-04-02T20:12:07Z
dc.date.issued2024
dc.description.abstractBackground Tenofovir/lamivudine/dolutegravir (TLD) is the preferred first-line antiretroviral therapy (ART) regimen for people with HIV (PWH), including those who were previously virologically suppressed on nonnucleoside reverse transcriptase inhibitors (NNRTIs). We sought to estimate the real-world effectiveness of the TLD transition in Ugandan public-sector clinics. Methods We conducted a prospective cohort study of PWH aged ≥18 years who were transitioned from NNRTI-based ART to TLD. Study visits were conducted on the day of TLD transition and 24 and 48 weeks later. The primary end point was viral suppression (<200 copies/mL) at 48 weeks. We collected blood for retrospective viral load (VL) assessment and conducted genotypic resistance tests for specimens with VL >500 copies/mL. Results We enrolled 500 participants (median age 47 years; 41% women). At 48 weeks after TLD transition, 94% of participants were in care with a VL <200 copies/mL (n = 469/500); 2% (n = 11/500) were lost from care or died; and only 2% (n = 9/500) had a VL >500 copies/mL. No incident resistance to DTG was identified. Few participants (2%, n = 9/500) discontinued TLD due to adverse events. Conclusions High rates of viral suppression, high tolerability, and lack of emergent drug resistance support use of TLD as the preferred first-line regimen in the region. Conclusions High rates of viral suppression, high tolerability, and lack of emergent drug resistance support use of TLD as the preferred first-line regimen in the region.
dc.identifier.citationMcCluskey, S. M., Muyindike, W. R., Nanfuka, V., Omoding, D., Komukama, N., Barigye, I. T., ... & Siedner, M. J. (2024). Population Effectiveness of Dolutegravir Implementation in Uganda: A Prospective Observational Cohort Study (DISCO), 48-Week Results. The Journal of Infectious Diseases, 230(3), e622-e630. https://doi.org/10.1093/infdis/jiae260
dc.identifier.urihttps://doi.org/10.1093/infdis/jiae260
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/10324
dc.language.isoen
dc.publisherThe Journal of Infectious Diseases
dc.titlePopulation Effectiveness of Dolutegravir Implementation in Uganda: A Prospective Observational Cohort Study (DISCO), 48-Week Results
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Population Effectiveness of Dolutegravir Implementation.pdf
Size:
561.19 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences